FDA Panel's Doubts on Antidepressants in Pregnancy Raise Concerns
TL;DR Summary
An FDA panel questioned the safety of SSRIs during pregnancy, citing studies that many experts say are misrepresented or flawed, leading to criticism from medical societies. Most evidence indicates SSRIs are safe for pregnant women, and untreated depression poses significant health risks. Experts emphasize the importance of accurate information and a range of treatment options, including therapy and medication, to support maternal mental health.
- An FDA panel spread misinformation about SSRI use in pregnancy, alarming doctors NPR
- How FDA panelists casting doubt on antidepressant use during pregnancy could lead to devastating outcomes for mothers The Conversation
- FDA considers warning about antidepressants during pregnancy NewsNation
- Experts express concern after FDA panel questions use of SSIRs during pregnancy Spectrum News NY1
- Opinion | The F.D.A.’s Panel on Antidepressants During Pregnancy Was Alarmingly Biased The New York Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
5 min
vs 6 min read
Condensed
94%
1,042 → 64 words
Want the full story? Read the original article
Read on NPR